Reduced number of circulating endothelial progenitor cells (CD133+/KDR+) in patients with plaque psoriasis

Dermatology

Volumn 225, Issue 1, 2012, Pages 88-92

  Batycka Baran, Aleksandra ^a   Paprocka, Maria ^b   Krawczenko, Agnieszka ^b   Kantor, Aneta ^b   Duś, Danuta ^b   Szepietowski, Jacek C ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Atherosclerosis; Cardiovascular risk; Circulating endothelial progenitor cells; Endothelial dysfunction; Psoriasis

Indexed keywords

CD133 ANTIGEN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; BLOOD; CELL COUNT; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS VULGARIS;

ADULT; ANTIGENS, CD; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GLYCOPROTEINS; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PSORIASIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84867746698     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000341534     Document Type: Article

References (30)

1. Davidovici BB, Sattar N, Prinz JC, Puig L, Emery P, Barker JN, et al: Psoriasis and systemic inflammatory diseases: Potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 130: 1785-1796.
2. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG: Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009; 145: 700- 703.
3. Boehncke WH, Boehncke S, Tobin AM, Kirby B: The 'psoriatic march': A concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011; 20: 303- 307.
4. Hansson GK, Hermansson A: The immune system in atherosclerosis. Nat Immunol 2011; 12: 204-212.
5. Endemann DH, Schiffrin EL: Endothelial dysfunction. J Am Soc Nephrol 2004; 15: 1983-1992.
6. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-228. (Pubitemid 29377293)
7. Siddique A, Shantsila E, Lip GY, Varma C: Endothelial progenitor cells: What use for the cardiologist? J Angiogenes Res 2010; 22: 2-6.
8. Sen S, McDonald SP, Coates PT, Bonder CS: Endothelial progenitor cells: Novel biomarker and promising cell therapy for cardiovascular disease. Clin Sci (Lond) 2011; 120: 263- 283.
9. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A: Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999-1007. (Pubitemid 41262334)
10. Yiu KH, Yeung CK, Chan HT, Wong RM, Tam S, Lam KF, et al: Increased arterial stiffness in patients with psoriasis is associated with active systemic inflammation. Br J Dermatol 2011; 164: 514-520.
11. Distler JH, Beyer C, Schett G, Lüscher TF, Gay S, Distler O: Endothelial progenitor cells: Novel players in the pathogenesis of rheumatic diseases. Arthritis Rheum 2009; 60: 3168-3179.
12. Pákozdi A, Besenyei T, Paragh G, Koch AE, Szekanecz Z: Endothelial progenitor cells in arthritis-associated vasculogenesis and atherosclerosis. Joint Bone Spine 2009; 76: 581- 583.
13. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N: Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337-3347. (Pubitemid 43739380)
14. Mok MY, Yiu KH, Wong CY, Qiuwaxi J, Lai WH, Wong WS, et al: Low circulating level of CD133+KDR+cells in patients with systemic sclerosis. Clin Exp Rheumatol 2010; 28: 19-25.
15. Ablin JN, Goldstein Z, Aloush V, Matz H, Elkayam O, Caspi D, et al: Normal levels and function of endothelial progenitor cells in patients with psoriatic arthritis. Rheumatol Int 2009; 29: 257-262.
16. Timmermans F, Plum J, Yöder MC, Ingram DA, Vandekerckhove B, Case J: Endothelial progenitor cells: Identity defined? J Cell Mol Med 2009; 13: 87-102.
17. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, et al: Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000; 95: 952-958. (Pubitemid 30062717)
18. Friedrich EB, Walenta K, Scharlau J, Nickenig G, Werner N: CD34-/CD133+/ VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res 2006; 98: 20-25.
19. Borská L, Fiala Z, Krejsek J, Andrýs C, Vokurková D, Hamáková K, et al: Selected immunological changes in patients with Goeckerman's therapy TNF-alpha, sE-selectin, sP-selectin, sICAM-1 and IL-8. Physiol Res 2006; 55: 699-706. (Pubitemid 46021230)
20. Mussi A, Bonifati C, Carducci M, D'Agosto G, Pimpinelli F, D'Urso D, et al: Serum TNFalpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997; 11: 115-118. (Pubitemid 28045966)
21. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, et al: C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: Further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004; 109: 2058-2067. (Pubitemid 38620212)
22. Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Seidinger D, et al: Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 2005; 111: 204-211. (Pubitemid 40139733)
23. Ablin JN, Boguslavski V, Aloush V, Elkayam O, Paran D, Caspi D, George J: Effect of anti-TNF-alpha treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci 2006; 79: 2364-2369. (Pubitemid 44772932)
24. Mazzoccoli G, Notarsanto I, de Pinto GD, Dagostino MP, De Cata A, D'Alessandro G, et al: Anti-tumor necrosis factor- therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients. Intern Emerg Med 2010; 5: 495-500.
25. Kerekes G, Soltész P, Dér H, Veres K, Szabó Z, Végvári A, et al: Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann NY Acad Sci 2009; 1173: 814-821.
26. Heidenreich R, Röcken M, Ghoreschi K: Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol 2009; 90: 232-248.
27. Silverman MD, Haas CS, Rad AM, Arbab AS, Koch AE: The role of vascular cell adhesion molecule 1/very late activation antigen 4 in endothelial progenitor cell recruitment to rheumatoid arthritis synovium. Arthritis Rheum 2007; 56: 1817-1826. (Pubitemid 47110381)
28. Nowak K, Rafat N, Belle S, Weiss C, Hanusch C, Hohenberger P: Circulating endothelial progenitor cells are increased in human lung cancer and correlate with stage of disease. J Cardiothorac Surg 2010; 37: 758-763.
29. Barleon B, Reusch P, Totzke F, Herzog C, Keck C, Martiny-Baron G, et al: Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis 2001; 4: 143-154. (Pubitemid 34032700)
30. Flisiak I, Zaniewski P, Rogalska M, Myśliwiec H, Jaroszewicz J, Chodynicka B: Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales. Cytokine 2010; 52: 225-229.